- Home
- SNEX vs MRUS Comparison
SNEX vs MRUS Comparison
Compare SNEX & MRUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNEX
- MRUS
- Stock Information
- Founded
- SNEX 1924
- MRUS 2003
- Country
- SNEX United States
- MRUS Netherlands
- Employees
- SNEX N/A
- MRUS N/A
- Industry
- SNEX Investment Bankers/Brokers/Service
- MRUS Biotechnology: Pharmaceutical Preparations
- Sector
- SNEX Finance
- MRUS Health Care
- Exchange
- SNEX Nasdaq
- MRUS Nasdaq
- Market Cap
- SNEX 3.3B
- MRUS 2.8B
- IPO Year
- SNEX 1994
- MRUS 2016
- Fundamental
- Price
- SNEX $123.82
- MRUS $47.37
- Analyst Decision
- SNEX
- MRUS Strong Buy
- Analyst Count
- SNEX 0
- MRUS 13
- Target Price
- SNEX N/A
- MRUS $85.67
- AVG Volume (30 Days)
- SNEX 242.6K
- MRUS 526.2K
- Earning Date
- SNEX 02-05-2025
- MRUS 03-07-2025
- Dividend Yield
- SNEX N/A
- MRUS N/A
- EPS Growth
- SNEX 16.78
- MRUS N/A
- EPS
- SNEX 8.38
- MRUS N/A
- Revenue
- SNEX $106,994,400,000.00
- MRUS $35,932,000.00
- Revenue This Year
- SNEX N/A
- MRUS N/A
- Revenue Next Year
- SNEX $1.94
- MRUS $42.15
- P/E Ratio
- SNEX $14.77
- MRUS N/A
- Revenue Growth
- SNEX 60.95
- MRUS N/A
- 52 Week Low
- SNEX $64.03
- MRUS $37.77
- 52 Week High
- SNEX $128.23
- MRUS $61.61
- Technical
- Relative Strength Index (RSI)
- SNEX 67.39
- MRUS 71.36
- Support Level
- SNEX $115.81
- MRUS $39.67
- Resistance Level
- SNEX $121.97
- MRUS $41.15
- Average True Range (ATR)
- SNEX 4.01
- MRUS 1.71
- MACD
- SNEX 0.66
- MRUS 0.86
- Stochastic Oscillator
- SNEX 80.60
- MRUS 91.57
About SNEX StoneX Group Inc.
StoneX Group Inc is a Global brokerage and financial services firm. Its service offerings are execution, OTC / Market-Making, advisory services, Global payment solutions, market intelligence, Physical Trading and clearing services. The firm operates in four segments: Commercial, Institutional, Self-Directed/Retail, and Payments. Its customers include governmental and nongovernmental organizations, commercial banks, brokers, institutional investors, and investment banks. The company operates in the United States, South America, Europe, the Middle East and Asia, and other countries, out of which the majority of revenue is generated from the Middle East and Asia Region.
About MRUS Merus N.V.
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.